Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

107.96
-0.4400-0.41%
Volume:199.41K
Turnover:21.58M
Market Cap:4.91B
PE:52.66
High:108.67
Open:108.13
Low:106.84
Close:108.40
52wk High:109.57
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.21
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.86
PE(LYR):52.66

Loading ...

Haemonetics director Charles Dockendorff to step down from board at annual meeting

Reuters
·
May 02

Earning Preview: Haemonetics this quarter’s revenue is expected to increase by 2.27%, and institutional views are bullish

Earnings Agent
·
May 01

Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing

Simply Wall St.
·
Apr 29

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

GlobeNewswire
·
Apr 27

Haemonetics study shows VASCADE MVP XL outperforms VASCADE MVP in large-bore venous closure

Reuters
·
Apr 24

GVS FY25 net profit drops to EUR 18.4 million; revenue slips to EUR 424.7 million

Reuters
·
Apr 24

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

GlobeNewswire
·
Apr 20

Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating

TIPRANKS
·
Apr 16

BTIG Reaffirms Their Buy Rating on Haemonetics (HAE)

TIPRANKS
·
Apr 13

Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors

TIPRANKS
·
Apr 08

Haemonetics price target lowered to $64 from $70 at Citi

TIPRANKS
·
Apr 07

Orchestra BioMed presentation highlights pivotal trials for hypertension pacing, sirolimus artery therapy

Reuters
·
Apr 06

Does CHAPTER-3 Enrollment Milestone and Pipeline Progress Change The Bull Case For Pharvaris (PHVS)?

Simply Wall St.
·
Apr 05

Press Release: Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Apr 02

Haemonetics sets earnings release, conference call for fiscal Q4, full-year results

Reuters
·
Apr 02

Haemonetics wins FDA label expansion for VASCADE MVP XL venous closure system

Reuters
·
Mar 31

Haemonetics Receives FDA Approval for Expanded Labeling of the Vascade Mvp® Xl Venous Vascular Closure System

THOMSON REUTERS
·
Mar 31

A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Mar 27

Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista

TIPRANKS
·
Mar 26

Italy's GVS FY revenue rises on healthcare & life sciences strength

Reuters
·
Mar 26